期刊文献+

某院处方前置审核系统审核门急诊处方的效果和问题分析 被引量:4

Effects and Problems Analysis of Pre-examination System of Outpatient and Emergency Prescription in a Hospital
下载PDF
导出
摘要 目的:探索本院门急诊运用处方前置审核系统审理处方的效果与问题分析,使系统运行更规范化。方法:选取本院2019年1~6月未使用前置审核系统审核处方(316769张)和2021年1~6月运用前置审核系统审核处方(319524张)的效果分析。结果:本院2019年1~6月人工审核处方的合格率为91.77%,而2021年1~6月运用前置审核系统审核处方的合格率为98.44%,处方合格率有所提升。对比处方量排名前6位的科室,儿科与消化内科处方合格率提高了8.86%和11.72%。结论:处方前置审核系统能显著改善临床安全用药。 Objective:To explore the eff ect and existing problems of pre-examination system of outpatient and emergency pre scription in hospital,in order to make the pre-examination system more standardized.Methods:The results of 316769 prescriptions without the pre-examination system in our hospital from January to June 2019 and 319524 prescriptions which using the pre-examination system in our hospital from January to June 2021 were analyzed.Results:The qualifi ed rate of prescriptions from January to June 2019 in our hospital was 91.77%;however,from January to June in 2021,the qualifi ed rate of prescriptions checked by the pre-examination system was 98.44%,and the qualifi ed rate of prescriptions was improved.Comparing the top six departments with the largest prescriptions,the qualifi ed rate of prescriptions in pediatrics and gastroenterology department increased by 8.86%and 11.72%,respectively.Conclusion:The operation of preexamination system can improve the clinical safety of drug use.
作者 王文鸽 樊锐敏 刘欣 李玉强 WANG Wen-ge;FAN Rui-min;LIU Xin;LI Yu-qiang(Department of Pharmacy,the First People’s Hospital of Pingdingshan,Pingdingshan 467000,China)
出处 《中国合理用药探索》 2022年第7期107-112,共6页 Chinese Journal of Rational Drug Use
关键词 前置审核系统 效果 问题分析 处方 门急诊 the pre-examination system eff ects problems analysis prescriptions outpatient and emergency
  • 相关文献

参考文献12

二级参考文献120

  • 1周自强,胡大一,陈捷,张仁汉,李奎宝,赵秀丽.中国心房颤动现状的流行病学研究[J].中华内科杂志,2004,43(7):491-494. 被引量:1401
  • 2俞恩珠,胡毅坚.134例药物不良反应报告的分析[J].中国药物滥用防治杂志,2006,12(3):176-177. 被引量:3
  • 3Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as anindependent risk factor for stroke : the Framingham Study. Stroke,1991,22:983-988.
  • 4Xu G, Liu X,Wu W, et al. Recurrence after ischemic stroke inChinese patients : impact of uncontrolled modifiable risk factors.Cerebrovasc Dis,2007 ,23 : 117-120.
  • 5Lansberg MG, O'Donnell MJ, Khatri P,et al. Antithrombotic andthrombolytic therapy for ischemic stroke : Antithrombotic Therapyand Prevention of Thrombosis, 9th ed : American College of ChestPhysicians Evidence-Based Clinical Practice Guidelines. Chest,2012,141(2 Suppl) : e601S-636S.
  • 6Camm AJ, Lip GY, De Caterina R, et al. 2012 focused update ofthe ESC Guidelines for the management of atrial fibrillation : anupdate of the 2010 ESC Guidelines for the management of atrialfibrillation-developed with the special contribution of the EuropeanHeart Rhythm Association. Europace, 2012 ,14 : 1385-1413.
  • 7McCart GM, Kayser SR. Therapeutic equivalency of low-molecular-weight heparins. Ann Pharmacother, 2002 , 36: 1042-1057.
  • 8Ieko M , Tarumi T, Takeda M, et al. Synthetic selective inhibitorsof coagulation factor X a strongly inhibit thrombin generationwithout affecting initial thrombin forming time necessary for plateletactivation in hemostasis. J Thromb Haemost, 2004,2:612-618.
  • 9Turpie AG. Oral,direct factor X a inhibitors in development forthe prevention and treatment of thromboembolic diseases.Arterioscler Thromb Vase Biol, 2007 , 27 :1238-1247.
  • 10Kubitza D, Becka M, Wensing G, et al. Safety,pharmacodynamics, and pharmacokinetics of BAY 59-7939-anoral,direct Factor X a inhibitor-after multiple dosing in healthymale subjects. Eur J Clin Pharmacol, 2005,61 : 873-880.

共引文献308

同被引文献48

引证文献4

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部